# Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo

Page: https://stenobird.com/podcast/the-uromigos-1214845/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo
Text version: https://stenobird.com/podcast/the-uromigos-1214845/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo.md
Podcast: [The Uromigos](https://stenobird.com/podcast/the-uromigos-1214845)
Published: 2026-02-28T18:30:00+00:00
Episode link: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-485-ASCO-GU-2026---LITESPARK-011-LenBelzu-vs-Cabo-e3fk2k7
Audio file: https://anchor.fm/s/13347ea8/podcast/play/116049991/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-25%2F418830529-44100-2-b7c309b2e3b3a.m4a
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo
Duration seconds: 1887

## Resource

This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan plus Lenvatnib versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-uromigos-1214845/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.